Skip to main content

Main navigation

  • About
    • Members
    • Our Team
    • Annual Report
    • Rutgers-NPC Health Policy & Communications Fellowship
    • NPC Summer Scholars
    • Contact Us
  • Topics
    • Health Spending
      • IRA & Medicare Drug Price Negotiation
      • 340B Drug Pricing Program
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient-Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Fact Sheets
    • Policy & Evidence Briefs
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Newsletters
    • Events
    • CER Daily Newsfeed®
    • Press Room
      • NPC in the News
      • NPC Press Releases
    • Videos and Graphics
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

The Certainty of Uncertainty in Health Technology Assessment 

  • Read more about The Certainty of Uncertainty in Health Technology Assessment 

Talking Points on the Drug Pricing Provisions in the Build Back Better Act

  • Read more about Talking Points on the Drug Pricing Provisions in the Build Back Better Act

Drug Spending Mirrors Spending on Other Health Care Services

  • Read more about Drug Spending Mirrors Spending on Other Health Care Services

Health Spending for Commercial Plans Is Predominantly Concentrated In Small Population of High-Intensity Consumers

  • Read more about Health Spending for Commercial Plans Is Predominantly Concentrated In Small Population of High-Intensity Consumers

Domestic Reference Pricing Talking Points

  • Read more about Domestic Reference Pricing Talking Points

Price Regulation Talking Points

  • Read more about Price Regulation Talking Points

Health Care Stakeholders Can Learn from Pharmacists’ Patient-Centered Perspective

  • Read more about Health Care Stakeholders Can Learn from Pharmacists’ Patient-Centered Perspective

Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health

  • Read more about Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health

Going Below The Surface

  • Read more about Going Below The Surface

Going Below The Surface E-newsletter: August 2019

  • Read more about Going Below The Surface E-newsletter: August 2019

Pagination

  • Next page
  • Page 7
  • Next page
Subscribe to Health Spending

Let's stay in touch.

Subscribe to our newsletter.
© 2026 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter image/svg+xml
  • Linkedin
  • Youtube